AEMETIS, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AEMETIS, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $77.19M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $28.11M | Mar 29, 2024 |
| FY2021 | Dec 31, 2021 | $211.95M | Mar 10, 2022 |
| FY2021 | Dec 31, 2020 | $165.56M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $202.00M | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | $171.53M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $150.16M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $143.16M | Mar 29, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $150.16M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $143.16M | Mar 29, 2018 |
| FY2015 | Dec 31, 2015 | $35.35M | Mar 29, 2016 |
| FY2015 | Sep 30, 2015 | $38.51M | Mar 29, 2016 |
| FY2015 | Jun 30, 2015 | $38.07M | Mar 29, 2016 |
| FY2015 | Mar 31, 2015 | $34.73M | Mar 29, 2016 |
| FY2015 | Dec 31, 2014 | $41.48M | Mar 29, 2016 |
| FY2015 | Sep 30, 2014 | $48.35M | Mar 29, 2016 |
| FY2015 | Jun 30, 2014 | $57.20M | Mar 29, 2016 |
| FY2015 | Mar 31, 2014 | $60.67M | Mar 29, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($768.0K) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($580.0K) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.02M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($5.54M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $7.94M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $11.03M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $12.70M | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | $5.41M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $3.38M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $11.60M | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($77.00M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($87.54M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($46.42M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($107.76M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($47.15M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($36.66M) | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | ($39.48M) | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | ($36.29M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($31.77M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($15.64M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($37.22M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($40.42M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($37.40M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($34.40M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($15.83M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($6.07M) | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | ($4.93M) | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | ($10.93M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($12.18M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($781.0K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $152.0K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $180.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $88.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $213.0K | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $205.0K | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | $246.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $2.37M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $369.0K | Mar 29, 2018 |
| FY2015 | Dec 31, 2015 | $117.0K | Mar 29, 2016 |
| FY2015 | Sep 30, 2015 | $117.0K | Mar 29, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $39.84M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $39.42M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $28.69M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $23.68M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $16.88M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $17.42M | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | $16.09M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $13.19M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $12.01M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.26M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($32.93M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $13.83M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($22.87M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($20.65M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $2.48M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | ($2.03M) | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | ($5.51M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($8.69M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $371.0K | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.00M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $20.25M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $33.12M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $39.16M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $26.65M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $19.34M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $8.58M | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | $4.07M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $1.12M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $629.0K | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $259.84M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $259.30M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $243.41M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $207.11M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $160.83M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $125.14M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $99.90M | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | $91.82M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $94.33M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $77.81M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($306.83M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($263.93M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($216.98M) | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | ($201.85M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($120.24M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($184.74M) | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | ($154.37M) | Mar 10, 2022 |
| FY2021 | Dec 31, 2018 | ($115.58M) | Mar 10, 2022 |
| FY2018 | Dec 31, 2017 | ($78.39M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($49.81M) | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $0 | Mar 29, 2016 |
| FY2015 | Dec 31, 2014 | $968.0K | Mar 29, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($639.94M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($562.94M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($475.41M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($428.99M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($321.23M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($274.08M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($237.42M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($193.20M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($160.19M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($129.89M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.89M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $898.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.67M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.31M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $7.75M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $592.0K | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $656.0K | Mar 10, 2022 |
| FY2021 | Dec 31, 2018 | $1.19M | Mar 10, 2022 |
| FY2019 | Dec 31, 2017 | $428.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $1.49M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $338.06M | Mar 14, 2025 |
| FY2023 | Dec 31, 2023 | $294.72M | Mar 29, 2024 |
| FY2022 | Dec 31, 2022 | $246.24M | Mar 9, 2023 |
| FY2021 | Dec 31, 2021 | $189.70M | Mar 10, 2022 |
| FY2020 | Dec 31, 2020 | $230.07M | Mar 15, 2021 |
| FY2019 | Dec 31, 2019 | $179.69M | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $157.82M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $138.16M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $100.31M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $88.95M | Mar 17, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | (1) | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | (1) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | (1) | Mar 10, 2022 |
| FY2019 | Dec 31, 2018 | (1) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | (1) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66.19M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 51.14M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 40.97M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 35.87M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 33.46M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 22,830 | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 20,570 | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 20,345 | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 20,088 | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 19,858 | Mar 29, 2018 |